Free Trial
NASDAQ:ONCT

Oncternal Therapeutics (ONCT) Stock Price, News & Analysis

Oncternal Therapeutics logo
$0.53 0.00 (0.00%)
As of 04/29/2025

About Oncternal Therapeutics Stock (NASDAQ:ONCT)

Key Stats

Today's Range
$0.53
$0.53
50-Day Range
$0.53
$0.53
52-Week Range
$0.53
$7.79
Volume
N/A
Average Volume
88,233 shs
Market Capitalization
$1.56 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00
Consensus Rating
Hold

Company Overview

Oncternal Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
35th Percentile Overall Score

ONCT MarketRank™: 

Oncternal Therapeutics scored higher than 35% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Oncternal Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 1 buy rating, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Oncternal Therapeutics has received no research coverage in the past 90 days.

  • Read more about Oncternal Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Oncternal Therapeutics are expected to grow in the coming year, from ($12.43) to ($10.25) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Oncternal Therapeutics is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Oncternal Therapeutics is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Oncternal Therapeutics has a P/B Ratio of 0.05. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for ONCT.
  • Dividend Yield

    Oncternal Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Oncternal Therapeutics does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for ONCT.
  • News Sentiment

    Oncternal Therapeutics has a news sentiment score of -0.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Oncternal Therapeutics this week, compared to 0 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Oncternal Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    11.20% of the stock of Oncternal Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 16.05% of the stock of Oncternal Therapeutics is held by institutions.

  • Read more about Oncternal Therapeutics' insider trading history.
Receive ONCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oncternal Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ONCT Stock News Headlines

I was wrong about Trump
I made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his advisors, I believed him. I believed the promise that he would finally confront the single most dangerous threat to American life. That he would fix the ticking time bomb I’ve been warning about for 15 years. But I was wrong.
Oncternal Therapeutics Reports Q3 2024 Earnings
See More Headlines

ONCT Stock Analysis - Frequently Asked Questions

Oncternal Therapeutics' stock was trading at $0.5266 at the start of the year. Since then, ONCT shares have increased by 0.0% and is now trading at $0.5266.

Oncternal Therapeutics, Inc. (NASDAQ:ONCT) announced its quarterly earnings results on Thursday, August, 8th. The company reported ($2.89) EPS for the quarter, topping the consensus estimate of ($3.03) by $0.14. The company had revenue of $0.80 million for the quarter, compared to analyst estimates of $0.24 million. Oncternal Therapeutics had a negative net margin of 1,599.95% and a negative trailing twelve-month return on equity of 177.58%.
Read the conference call transcript
.

Oncternal Therapeutics shares reverse split on the morning of Monday, January 8th 2024.The 1-20 reverse split was announced on Monday, January 8th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, January 8th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Shares of ONCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Oncternal Therapeutics investors own include NIO (NIO), Walt Disney (DIS), Tesla (TSLA), Plug Power (PLUG), Meta Platforms (META) and Moderna (MRNA).

Company Calendar

Last Earnings
8/08/2024
Today
7/03/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ONCT
Employees
30
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.00
High Stock Price Target
$18.00
Low Stock Price Target
$2.00
Potential Upside/Downside
+1,799.0%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
4 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$39.48 million
Net Margins
-1,599.95%
Pretax Margin
-1,599.95%

Debt

Sales & Book Value

Annual Sales
$790 thousand
Price / Cash Flow
N/A
Book Value
$10.19 per share
Price / Book
0.05

Miscellaneous

Free Float
2,628,000
Market Cap
$1.56 million
Optionable
No Data
Beta
1.18
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:ONCT) was last updated on 7/4/2025 by MarketBeat.com Staff
From Our Partners